Legal Powerhouses in Play
Pfizer is represented by a formidable team from Wachtell Lipton Rosen & Katz — including Jonathan M. Moses, Ryan A. McLeod, Carrie M. Reilly, and Adam L. Goodman — alongside Kevin R. Shannon, Berton W. Ashman Jr., Mathew A. Golden, and Callan R. Jackson of Potter Anderson & Corroon LLP.
Novo Nordisk has enlisted David E. Ross of Kasowitz LLP and Michael Sirkin of Ross Aronstam & Moritz LLP, while Metsera Inc. is represented by Daniel A. Mason, Miranda N. Gilbert, and Spencer V. Crawford of Paul Weiss Rifkind Wharton & Garrison LLP.
A Pharmaceutical Power Struggle With Billions at Stake
As the court awaits its next move, the Pfizer Weight-Loss $9B suit represents more than a corporate standoff — it’s a clash of titans for dominance in one of the world’s fastest-growing medical markets.
Behind the legal filings and billion-dollar offers lies a high-stakes race to control the future of obesity treatment, where each ruling could shift not only corporate fortunes but also the landscape of global health innovation.
